Literature DB >> 11818390

Change in full-field ERGs after macular translocation surgery with 360 degrees retinotomy.

Hiroko Terasaki1, Yozo Miyake, Toshimitsu Suzuki, Takashi Niwa, Chang-Hua Piao, Satoshi Suzuki, Makoto Nakamura, Mineo Kondo.   

Abstract

PURPOSE: One of the methods used in macular translocation (MT) surgery for subfoveal neovascularization is to create a temporary total retinal detachment followed by a 360 degrees retinotomy. The whole retina is then shifted from the original surface of the retinal pigment epithelium (RPE), resulting in an unusual retina and RPE complex. The purpose of this study was to assess retinal function after MT surgery.
METHODS: Full-field electroretinograms (ERGs) were recorded before and 4 to 8 months (mean, 5.4 months) after MT surgery with a 360 degrees retinotomy in 15 consecutive patients with age-related macular degeneration (10 eyes), high myopia (4 eyes), and polypoidal choroidal vasculopathy (1 eye). Their ages ranged from 57 to 74 years. The angle of rotation of the retina ranged from 18 degrees to 45 degrees (mean +/- SE, 30 +/- 2 degrees). In addition to the recording of the standard rod and mixed rod-cone ERGs after 30 minutes of dark adaptation, the cone single flash and 30-Hz flicker ERGs were recorded immediately after a light-adapting background was turned on (LA(0)) and also after 10 minutes of light adaptation (LA(10)).
RESULTS: The mean amplitude of the full-field ERGs was reduced after surgery by 44% for the rod response, by 24% for the mixed rod-cone b-wave, by 12% and 35% for the cone single-flash b-wave at LA(0) and 30-Hz flicker ERGs at LA(0), respectively. The mean implicit times were delayed by 8 msec for the rod response, by 2 msec for the mixed rod-cone oscillatory potential (OP1), by 4 msec for the cone single-flash b-wave at LA(0), and by 6 msec for the 30-Hz flicker at LA(0).
CONCLUSIONS: These results demonstrated a functional alteration in both the rod and cone components of the ERGs for the entire retina after MT surgery.

Entities:  

Mesh:

Year:  2002        PMID: 11818390

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration.

Authors:  K Takeuchi; S Kachi; E Iwata; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

2.  Electroretinogram changes after scleral buckling surgery of retinal detachment.

Authors:  Yuanyuan Gong; Xingwei Wu; Xiaodong Sun; Xi Zhang; Ping Zhu
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

3.  Magnetic resonance imaging of the extraocular muscle path before and after strabismus surgery for a large degree of cyclotorsion induced by macular translocation surgery.

Authors:  Emi Amano Iwata; Miho Sato; Kiyoko Ukai; Hiroko Terasaki
Journal:  Jpn J Ophthalmol       Date:  2009-03-31       Impact factor: 2.447

4.  Displacement of foveal area toward optic disc after macular hole surgery with internal limiting membrane peeling.

Authors:  K Kawano; Y Ito; M Kondo; K Ishikawa; S Kachi; S Ueno; Y Iguchi; H Terasaki
Journal:  Eye (Lond)       Date:  2013-05-24       Impact factor: 3.775

5.  Case selection in macular relocation surgery for age related macular degeneration.

Authors:  D Wong; P Stanga; M Briggs; P Lenfestey; E Lancaster; K K Li; K S Lim; C Groenewald
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

6.  The role of the ERG in the diagnosis and treatment of Age-Related Macular Degeneration.

Authors:  Christina Gerth
Journal:  Doc Ophthalmol       Date:  2008-06-07       Impact factor: 2.379

7.  Preservation of photoreceptors in dystrophic RCS rats following allo- and xenotransplantation of IPE cells.

Authors:  Gabriele Thumann; Anna Katharina Salz; Peter Walter; Sandra Johnen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-26       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.